SynthesisJournal of the American Academy of Dermatology2020
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
Synthesis in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.International journal of molecular sciences · 2026Pooled it
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.Journal of the American Academy of Dermatology · 2021Guideline
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- The Association Between SARS-CoV-2 Exposure, COVID-19 Vaccination and Psoriatic Arthritis-A Nested Case-Control Study.Vaccines · 2026Article
- Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden.Lupus science & medicine · 2025Article
- Article
- Genetic Interactions of Phase II Xenobiotic-Metabolizing EnzymesJournal of xenobiotics · 2025Article
- MrgprA3 neurons drive cutaneous immunity against helminths through selective control of myeloid-derived IL-33.Nature immunology · 2024Article
- Article
- Early-Onset Generalized Pustular Psoriasis of Pregnancy Following Hydroxychloroquine Use.Annals of dermatology · 2023Article
- An Erythrodermic Psoriasis Flare-Up With Staphylococcus Bacteremia Secondary to COVID-19 Infection: A Case Report.Cureus · 2023Article
- Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.Clinical case reports · 2022Article
- Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus.Frontiers in medicine · 2022Review
- Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.The Journal of clinical and aesthetic dermatology · 2021Review
- How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study.Journal of cosmetic dermatology · 2021Observational
- Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.Dermatologic therapy · 2021Article
- Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin.Biologics : targets & therapy · 2021Article
- Generalized pustular psoriasis following COVID-19.Dermatologic therapy · 2021Article
- Psoriasis and COVID-19: A narrative review with treatment considerations.Dermatologic therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile evidence suggests that hydroxychloroquine (HCQ) may decrease the viral load in patients with a COVID-19 infection, a number of case reports indicate adverse dermatologic effects of this potential treatment.
objectiveTo conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment.
methodsEmbase and MEDLINE were comprehensively searched for original studies examining adverse effects of HCQ treatment related to psoriasis. Participant demographics and details of HCQ administration and psoriasis diagnosis were extracted from 15 articles representing 18 patients.
resultsWomen accounted for a significantly larger number of cases of psoriasis compared with men and unreported sex (14 [77.8%] vs 2 [11.1%] vs 2 [11.1%], respectively). In addition, 50% (n = 9) of the patients did not have a history of psoriasis before taking HCQ. Of the 18 patients, 9 (50.0%) experienced de novo psoriasis, 5 (27.8%) experienced exacerbation of psoriatic symptoms, and 4 (22.2%) had a relapse of psoriasis after HCQ administration.
conclusionHCQ treatment may result in induction, exacerbation, or relapse of psoriasis. Monitoring for adverse effects of HCQ treatment is necessary, and clinical trials are essential in characterizing the safety profile of HCQ use in patients with a COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.